Clinical trial · Interventional
Research of Circulating Tumor Cells Released During Cervical Cancer Surgery
Preliminary Descriptive Exploratory Pilot Study Research of Circulating Tumor Cells Released During Cervical Cancer Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cervical cancer is a rare pathology. Recent studies showed that the risk of recurrence is higher for patients treated by coelioscopy in comparison with laparotomy. It could be explained by the spread of circulating tumor cells (CTC) due to tumor mobilization during different steps of the surgery. The primary goal is to evaluate the spread of CTC during surgery on peripheral blood samples. The secondary outcome is to evaluation the disease-free survival at 3 and 5 years postoperatively. 20 patients with early stage cervical (IA1 to IB2) eligible to coelioscopic stadification and laparoscopic surgery will be included.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer Stage IA1 | Malignant Cervical Neoplasm | CURATED_BROADER | 0.78 |
| Cervical Cancer Stage IA2 | Malignant Cervical Neoplasm | CURATED_BROADER | 0.78 |
| Cervical Cancer Stage IB1 | Malignant Cervical Neoplasm | CURATED_BROADER | 0.78 |
| Cervical Cancer Stage IB2 | Malignant Cervical Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Early stage cervical cancer
- description
- Patients with cervical cancer eligible for surgery, stage IA1 to IB2
- interventionNames
- Other: Blood samples
Primary outcomes (1)
- measure
- Number of circulating tumor cell detected after cervical cancer surgery.
- timeFrame
- Within 48 hours after surgery.
- description
- Detection of the presence of at least one circulating tumor cell from blood samples taken during surgery (one CTC per 7.5mL of blood or increase of at least one CTC if CTC is present pre-operatively)
Secondary outcomes (1)
- measure
- Evaluation of disease-free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Woman \>18 years old * Cervical cancer confirmed by histology * Early stage eligible for immediate surgical treatment (or post-brachytherapy): stages IA1, 1A2, 1B1 and IB2 with or without emboli determined by MRI performed as part of the treatment * Histology : epidermoid carcinoma and adenocarcinoma * Valid Social Security * Wrote consent Exclusion Criteria: * Advanced stage (Stage IB3 and more) * Concomitant cancer * Pregnant or breastfeeding woman * Vulnerable person (Article L1121-6 of the Public Health Code) * Participation to other study with an exclusion period still in progress * Participation to other study that may have an impact on the prognosis of cervical cancer
References
Publications (0)
Data not yet available